GlassScriptPhysician profile
James Edward Canner
NPI 1568126639
$18,278.83
in general payments reported to CMS, 2019-2025
32 companies · $9,112 in 2025
The $9,112 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.11 · 2022: $1,618 · 2023: $1,248 · 2024: $6,248 · 2025: $9,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $1,233 · Education: $14.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,360.22 |
| Consulting Fee | $1,233.00 |
| Education | $14.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $3,663.22 | 2021-2025 | Dupixent |
| Abbvie INC. | $3,121.58 | 2022-2025 | |
| Genzyme Corporation | $1,805.56 | 2022-2025 | |
| Galderma Laboratories, L.P. | $1,351.44 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Dermavant Sciences, INC. | $873.57 | 2023-2024 | Vtama |
| Amgen INC. | $778.12 | 2024-2025 | Otezla, Otezla |
| Ucb, INC. | $703.29 | 2024-2025 | Bimzelx |
| Incyte Corporation | $661.20 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $610.19 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Journey Medical Corporation | $568.15 | 2022-2025 | |
| Leo Pharma INC. | $535.57 | 2021-2025 | Anzupgo, Adbry |
| Novartis Pharmaceuticals Corporation | $513.93 | 2022-2025 | |
| Janssen Biotech, INC. | $479.39 | 2024-2025 | Tremfya |
| Organon LLC | $371.79 | 2025 | Vtama |
| Mayne Pharma Commercial LLC | $361.87 | 2022-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $317.57 | 2023-2025 | Zoryve |
| Pfizer INC. | $271.96 | 2022-2025 | |
| Botanix Sb INC | $267.56 | 2025 | Sofdra |
| Viiv Healthcare Company | $253.96 | 2022-2025 | Apretude |
| E.R. Squibb & Sons, L.L.C. | $136.90 | 2024-2025 | Sotyktu |
| Idorsia Pharmaceuticals US INC | $128.33 | 2023 | Quviviq |
| Almirall LLC | $116.95 | 2022-2025 | Seysara, Klisyri |
| Gilead Sciences, INC. | $95.36 | 2023 | |
| Verrica Pharmaceuticals INC. | $65.65 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.33 | 2022-2025 | Siliq, Jublia, Cabtreo |
| Epi Health, LLC | $44.31 | 2022 | |
| Cipher Pharmaceuticals US LLC | $29.34 | 2025 | Natroba, Spinosad |
| Strata Skin Sciences, INC. | $27.23 | 2024 | Xtrac |
| Sun Pharmaceutical Industries INC. | $23.41 | 2025 | |
| Almatica Pharma LLC | $22.39 | 2023 | Gralise, Loreev Xr |
| Fidia Pharma USA INC. | $17.10 | 2025 | |
| Biofrontera INC. | $14.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Canner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.